2.66

0.76% +0.02

After Hours: 2.66

Intercure Ltd (INCR)

Overview News Price History Option Chain Discussions Forecast Stock Split

Intercure Ltd stock is currently priced at $2.66, with a 24-hour trading volume of 11,853. It has seen a +0.76% increased in the last 24 hours and a +4.31% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $2.65 pivot point. If it approaches the $2.68 resistance level, significant changes may occur.

Previous Close:

$2.64

Open:

$2.61

24h Volume:

11,853

Market Cap:

$121.22M

Revenue:

$118.18M

Net Income/Loss:

$5.99M

P/E Ratio:

20.17

EPS:

0.1319

Net Cash Flow:

$-12.91M

1W Performance:

+5.14%

1M Performance:

+4.31%

6M Performance:

+163.37%

1Y Performance:

+18.22%

1D Range:

$2.61

$2.70

52W Range:

$0.99

$2.9199

Intercure Ltd Stock (INCR) Company Profile

Name

Intercure Ltd

Sector

Healthcare (1191)

Industry

Drug Manufacturers - Specialty & Generic (4)

Phone

972 7 7460 5012

Address

85 Medinat ha-Yehudim Street, Herzliya

Employee

Twitter

Next Earnings Date

Latest SEC Filings

INCR's Discussions on Twitter

Intercure Ltd Stock (INCR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-18-22	Upgrade	Canaccord Genuity	Speculative Buy → Buy

Intercure Ltd Stock (INCR) Latest News

Intercure Ltd Stock (INCR) Financials Data

Intercure Ltd (INCR) Revenue 2024

INCR reported a revenue (TTM) of $118.18 million for the quarter ending June 30, 2023, a +17.94% rise year-over-year.

Intercure Ltd (INCR) Net Income 2024

INCR net income (TTM) was $5.99 million for the quarter ending June 30, 2023, a -18.87% decrease year-over-year.

Intercure Ltd (INCR) Cash Flow 2024

INCR recorded a free cash flow (TTM) of -$12.91 million for the quarter ending March 31, 2023, a -486.28% decrease year-over-year.

Intercure Ltd (INCR) Earnings per Share 2024

INCR earnings per share (TTM) was $0.1319 for the quarter ending June 30, 2023, a -28.70% decline year-over-year.

InterCure Ltd, together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Israel and internationally. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.